Meridian Medical Technologies
This article was originally published in The Gray Sheet
Firm recalls 47 lots of EpiPen and EpiPen Jr. auto-injectors because some of the devices "may not provide effective doses of medication to treat acute allergic emergencies (anaphylaxis)," the firm reports May 8. The Class I recall seeks to retrieve auto-injectors distributed in the U.S., Germany, Israel, Denmark, Canada, Turkey, Australia, Greece and South Africa. No patients have been affected by the problem, which "arose in the process of advancing our automated production capabilities," Meridian states
You may also be interested in...
Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.
With Warp Speed Decisions Already Made, Transitioning To Biden Admin Should Be No Trouble, Slaoui Says
As vaccines near availability, Moncef Slaoui says his full-time role at OWS may be ending. He has not met with the Biden Transition team, but notes that other Warp Speed officials have.
Strong top-line efficacy in pyruvate kinase deficiency patients who don’t receive regular transfusions looks approvable, analysts say, but Agios will await data in regularly transfused patients.